185104-11-4 | Acotiamide hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
100mg	98%	in stock	$26.00	$18.00
250mg	98%	in stock	$38.00	$26.00
1g	98%	in stock	$98.00	$68.00
5g	98%	in stock	$389.00	$272.00

Description

• Catalog Number: AB47676
• Chemical Name: Acotiamide hydrochloride
• CAS Number: 185104-11-4
• Molecular Formula: C21H31ClN4O5S
• Molecular Weight: 487.0126
• MDL Number: MFCD23103502
• SMILES: COc1cc(O)c(cc1OC)C(=O)Nc1scc(n1)C(=O)NCCN(C(C)C)C(C)C.Cl

Computed Properties

• Complexity: 586
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 10

Literature

• Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.

  Expert review of gastroenterology & hepatology 20120901

• A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.

  Gut 20120601

• New hope for functional dyspepsia?

  Gut 20120601

• Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20120601

• Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20120601

• Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.

  Journal of pharmaceutical sciences 20111101

• Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats.

  European journal of pharmacology 20110901

• Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.

  Expert opinion on investigational drugs 20110501

• Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride.

  The Journal of pharmacology and experimental therapeutics 20110301

• A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.

  Digestion 20110101

• Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100601

• Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100601

• Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20100101

• A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20090301

• Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080901

• Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes.

  European journal of pharmacology 20041128

• Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.

  European journal of pharmacology 20040823

• Z-338. Zeria/Yamanouchi.

  Current opinion in investigational drugs (London, England : 2000) 20040701

• Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach.

  Japanese journal of pharmacology 20020801

• An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338.

  British journal of pharmacology 20020301

• LC determination of Z-338, novel gastroprokinetic agent in dog plasma by SCX solid phase extraction.

  Journal of pharmaceutical and biomedical analysis 20010601